Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

An analysis of the polymorphisms of the GLUT1 gene in urothelial cell carcinomas of the bladder and its correlation with p53, Ki67 and GLUT1 expressions

Abstract

Frequencies of two glucose transporter 1 (GLUT1) single-nucleotide polymorphisms (SNPs) (XbaI G>T and HaeIII T>C) were studied with urothelial cell carcinomas of the bladder (UCC) and 204 normal persons. And the expression of the p53, Ki67 and GLUT1 was assayed by immunohistochemistry. The frequency of the TT genotype and T allele of the XbaI G>T SNP was decreased in the patients with UCC. The frequency of the CC genotype and C allele of the HaeIII T>C SNP was decreased in the patients with UCC. The GLUT1 XbaI genotype GG was more frequent in higher tumor stage and higher tumor grade patients. In the XbaI G>T SNP, the GG genotype was significantly related to higher Remmele immunoreactive score (IRS) of Ki67 and higher IRS of GLUT1. In conclusion, the TT genotype in XbaI G>T SNP and CC genotype of HaeIII T>C SNP may have protective effect in the carcinogenesis process of UCC. In the XbaI G>T SNP, the GG genotype of was positively related to tumor proliferation, glucose metabolism, tumor grade and stage. Therefore, the variant might become a possible proliferation-related prognostic factor for UCC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108.

    Article  Google Scholar 

  2. Amann T, Hellerbrand C . GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009; 13: 1411–1427.

    Article  CAS  Google Scholar 

  3. Reis H, Tschirdewahn S, Szarvas T, Rubben H, Schmid KW, Grabellus F . Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder. Oncol Lett 2011; 2: 1149–1153.

    Article  Google Scholar 

  4. Hodgkinson AD, Millward BA, Demaine AG . Polymorphisms of the glucose transporter (GLUT1) gene are associated with diabetic nephropathy. Kidney Int 2001; 59: 985–989.

    Article  CAS  Google Scholar 

  5. Ng DP, Canani L, Araki S, Smiles A, Moczulski D, Warram JH et al. Minor effect of GLUT1 polymorphisms on susceptibility to diabetic nephropathy in type 1 diabetes. Diabetes 2002; 51: 2264–2269.

    Article  CAS  Google Scholar 

  6. Rufino M, Hernandez D, Barrios Y, Salido E . The GLUT-1 XbaI gene polymorphism is associated with vascular calcifications in nondiabetic uremic patients. Nephron Clin Pract 2008; 108: c182–c187.

    Article  CAS  Google Scholar 

  7. Page T, Hodgkinson AD, Ollerenshaw M, Hammonds JC, Demaine AG . Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Cancer Genet Cytogenet 2005; 163: 151–155.

    Article  CAS  Google Scholar 

  8. Amann T, Kirovski G, Bosserhoff AK, Hellerbrand C . Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma. Mol Membr Biol 2011; 28: 182–186.

    Article  Google Scholar 

  9. Grabellus F, Sheu SY, Bachmann HS, Lehmann N, Otterbach F, Heusner TA et al. The XbaI G>T polymorphism of the glucose transporter 1 gene modulates 18F-FDG uptake and tumor aggressiveness in breast cancer. J Nucl Med 2010; 51: 1191–1197.

    Article  CAS  Google Scholar 

  10. Vousden KH, Ryan KM . p53 and metabolism. Nat Rev Cancer 2009; 9: 691–700.

    Article  CAS  Google Scholar 

  11. Feng Z, Levine AJ . The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010; 20: 427–434.

    Article  CAS  Google Scholar 

  12. Kruse JP, Gu W . p53 aerobics: the major tumor suppressor fuels your workout. Cell Metab 2006; 4: 1–3.

    Article  CAS  Google Scholar 

  13. Aylon Y, Oren M . New plays in the p53 theater. Curr Opin Genet Dev 2011; 21: 86–92.

    Article  CAS  Google Scholar 

  14. Friedrich MG, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Solter JK et al. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. European Urology 2001; 39: 159–166.

  15. Kilicli-Camur N, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 2002; 52: 463–469.

    Article  CAS  Google Scholar 

  16. Tuna B, Yorukoglu K, Tuzel E, Guray M, Mungan U, Kirkali Z. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract 2003; 199: 323–328.

    Article  CAS  Google Scholar 

  17. Binderup T, Knigge UP, Federspiel B, Sommer P, Hasselby JP, Loft A et al. Gene expression of glucose transporter 1 (GLUT1), hexokinase 1 and hexokinase 2 in gastroenteropancreatic neuroendocrine tumors: correlation with F-18-fluorodeoxyglucose positron emission tomography and cellular proliferation. Diagnostics 2013; 3: 372–384.

    Article  Google Scholar 

  18. Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. European Urol 1999; 36: 393–400.

    Article  CAS  Google Scholar 

  19. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 2000; 88: 2598–2605.

    Article  CAS  Google Scholar 

  20. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163: 758–760.

    Article  CAS  Google Scholar 

  21. Cheng L, Montironi R, Davidson DD, Lopez-Beltran A . Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol 2009; 22 (Suppl 2): S70–S95.

    Article  Google Scholar 

  22. Remmele W, Stegner HE . Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987; 8: 138–140.

    CAS  PubMed  Google Scholar 

  23. Grabellus F, Worm K, Schmid KW, Sheu SY . The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression. Thyroid 2012; 22: 377–382.

    Article  CAS  Google Scholar 

  24. Kim JW, Dang CV . Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927–8930.

    Article  CAS  Google Scholar 

  25. Brahimi-Horn MC, Chiche J, Pouyssegur J . Hypoxia signalling controls metabolicdemand. Curr Opin Cell Biol 2007; 19: 223–229.

    Article  CAS  Google Scholar 

  26. Grzeszczak W, Moczulski DK, Zychma M, Zukowska-Szczechowska E, Trautsolt W, Szydlowska I . Role of GLUT1 gene in susceptibility to diabetic nephropathy in type 2 diabetes. Kidney Int 2001; 59: 631–636.

    Article  CAS  Google Scholar 

  27. Friedrich MG, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Solter JK et al. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur Urol 2001; 39: 159–166.

    Article  CAS  Google Scholar 

  28. Kilicli-Camur N, Kilicaslan I, Gulluoglu MG, Esen T, Uysal V . Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 2002; 52: 463–469.

    Article  CAS  Google Scholar 

  29. Tuna B, Yorukoglu K, Tuzel E, Guray M, Mungan U, Kirkali Z . Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Prac 2003; 199: 323–328.

    Article  CAS  Google Scholar 

  30. Gontero P, Casetta G, Zitella A, Ballario R, Pacchioni D, Magnani C et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000; 38: 287–296.

    Article  CAS  Google Scholar 

  31. Yurakh AO, Ramos D, Calabuig-Farinas S, Lopez-Guerrero JA, Rubio J, Solsona E et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006; 50: 506–515.

    Article  CAS  Google Scholar 

  32. Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P . Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 1999; 36: 393–400.

    Article  CAS  Google Scholar 

  33. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP . MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 2000; 88: 2598–2605.

    Article  CAS  Google Scholar 

  34. Wu TT, Chen JH, Lee YH, Huang JK . The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000; 163: 758–760.

    Article  CAS  Google Scholar 

  35. Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006; 59: 83–88.

    Article  CAS  Google Scholar 

  36. Gonzalez-Campora R, Davalos-Casanova G, Beato-Moreno A, Luque RJ, Alvarez-Kindelan J, Requena MJ et al. Apoptotic and proliferation indexes in primary superficial bladder tumors. Cancer Lett 2006; 242: 266–272.

    Article  CAS  Google Scholar 

  37. Santos LL, Amaro T, Pereira SA, Lameiras CR, Lopes P, Bento MJ et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 2003; 29: 74–80.

    Article  CAS  Google Scholar 

  38. Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–1033.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to R Han or Y Sun.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, C., Yang, X., Wang, Y. et al. An analysis of the polymorphisms of the GLUT1 gene in urothelial cell carcinomas of the bladder and its correlation with p53, Ki67 and GLUT1 expressions. Cancer Gene Ther 24, 297–303 (2017). https://doi.org/10.1038/cgt.2017.17

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2017.17

This article is cited by

Search

Quick links